Guggenheim Reiterates “Buy” Rating for DBV Technologies (NASDAQ:DBVT)

DBV Technologies (NASDAQ:DBVT)‘s stock had its “buy” rating reaffirmed by investment analysts at Guggenheim in a research note issued to investors on Friday,Benzinga reports. They presently have a $51.00 price target on the stock. Guggenheim’s target price would suggest a potential upside of 155.00% from the company’s current price.

A number of other analysts have also recently commented on the company. Citigroup restated an “outperform” rating on shares of DBV Technologies in a research report on Wednesday, December 17th. Cantor Fitzgerald set a $48.00 price objective on DBV Technologies in a research note on Wednesday, December 17th. Wall Street Zen raised shares of DBV Technologies from a “sell” rating to a “hold” rating in a report on Sunday, February 8th. Citizens Jmp raised their target price on shares of DBV Technologies from $21.00 to $45.00 and gave the stock a “market outperform” rating in a research note on Wednesday, December 17th. Finally, HC Wainwright set a $40.00 price target on shares of DBV Technologies in a report on Thursday, December 18th. Two research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, one has given a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $38.65.

DBV Technologies Price Performance

Shares of DBVT stock opened at $20.00 on Friday. DBV Technologies has a 1 year low of $5.30 and a 1 year high of $26.18. The firm has a fifty day moving average price of $21.58 and a 200-day moving average price of $17.28. The company has a market cap of $1.11 billion, a price-to-earnings ratio of -3.83 and a beta of -0.97.

DBV Technologies (NASDAQ:DBVT) last announced its earnings results on Thursday, March 26th. The company reported ($1.15) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.96). DBV Technologies had a negative return on equity of 310.56% and a negative net margin of 2,606.83%.The company had revenue of $0.64 million during the quarter, compared to the consensus estimate of $1.06 million. Equities research analysts expect that DBV Technologies will post -7.05 EPS for the current year.

Institutional Trading of DBV Technologies

Institutional investors have recently made changes to their positions in the business. Artisan Partners Limited Partnership raised its stake in DBV Technologies by 6,273.4% during the 4th quarter. Artisan Partners Limited Partnership now owns 3,309,055 shares of the company’s stock valued at $63,435,000 after purchasing an additional 3,257,135 shares during the period. Vivo Capital LLC boosted its stake in DBV Technologies by 133.4% in the 4th quarter. Vivo Capital LLC now owns 2,461,626 shares of the company’s stock worth $47,189,000 after purchasing an additional 1,407,120 shares during the period. Siren L.L.C. bought a new position in DBV Technologies in the 4th quarter worth approximately $35,606,000. Adage Capital Partners GP L.L.C. purchased a new stake in DBV Technologies during the 2nd quarter valued at approximately $9,659,000. Finally, MPM Bioimpact LLC purchased a new stake in DBV Technologies during the 2nd quarter valued at approximately $9,649,000. Hedge funds and other institutional investors own 71.74% of the company’s stock.

More DBV Technologies News

Here are the key news stories impacting DBV Technologies this week:

• Positive Sentiment: VIASKIN peanut patch nearing FDA submission — media coverage highlights management preparing for a BLA/approval pathway and positions the peanut patch as a potential near-term commercial catalyst. DBV Technologies sets stage for ‘swift’ success as breakthrough peanut patch nears FDA submission
• Positive Sentiment: Citizens Jmp raised its price target to $47 and assigned a “market outperform” rating, signaling strong analyst conviction and implying substantial upside from current levels. Citizens Jmp price target raise
• Positive Sentiment: Guggenheim reaffirmed a “buy” rating and set a $51 price target, another high-end analyst endorsement that supports the bullish narrative around the peanut patch program. Guggenheim reiterates buy
• Positive Sentiment: Financial and operational update: DBV reports progress in toddler and child VIASKIN trials, strengthened leadership ahead of BLA submission, and disclosed cash of $194M plus $94M of additional proceeds (funding into Q2 2027) — improving near-term runway for regulatory activities. DBV Technologies Reports Full Year 2025 Financial Results and Business Update
• Neutral Sentiment: Regulatory/filing housekeeping — DBV filed its 2025 Form 10-K and Universal Registration Document (URD), making audited results and governance disclosures available to investors. This is procedural but important for due diligence. DBV Technologies Announces Filing of 2025 Annual Report on Form 10-K and Universal Registration Document
• Negative Sentiment: Quarterly results significantly missed expectations: EPS of ($4.43) vs. consensus ($0.19) and revenue $0.64M vs. $1.06M expected — very wide losses and negative margins raise near-term valuation and funding-scenario concerns despite the stated cash runway. DBV Technologies quarterly earnings press release

About DBV Technologies

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.